Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909924 | 1.00 | PREP (0.40) | PREPPOLBALDH1A1KMT2AMEN1 | |
| SCHEMBL474105 | 1.00 | PREP (0.40) | PREPPOLBALDH1A1KMT2AMEN1 | |
| SCHEMBL13899286 | 0.85 | PREP (0.38) | PREPALDH1A1KMT2ACA12CA1 | |
| SCHEMBL14445760 | 0.80 | POLB (0.54) | POLBALDH1A1KMT2AMEN1CA1 | |
| SCHEMBL1508406 | 0.78 | PREP (0.42) | PREPALDH1A1KMT2ACA12CA1 | |
| SCHEMBL4910148 | 0.78 | ACACB (0.43) | PREPALDH1A1KMT2AMEN1ACACB | |
| SCHEMBL7455145 | 0.77 | PREP (0.41) | PREPALDH1A1KMT2ACA12CA1 | |
| SCHEMBL7237737 | 0.77 | PREP (0.41) | PREPALDH1A1KMT2ACA12CA1 | |
| SCHEMBL12003862 | 0.77 | ALDH1A1 (0.50) | POLBALDH1A1NPSR1CYP1A2LMNA | |
| SCHEMBL1816436 | 0.77 | ALDH1A1 (0.50) | POLBALDH1A1NPSR1CYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1531810-B1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7507757-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1531810-A4 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20050119312-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2005-06-02 | — | — | US | disclosed |
| EP-1531810-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-25 | — | — | EP | disclosed |
| US-6875782-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040063762-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004004655-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063762-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | GLP1R, ZYX, SLC5A2 | PREP 4001/4885POLB 3836/4885ALDH1A1 3947/4885 |
| US-20050119312-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | NPY4R, XDH, GPR119 | PREP 3452/4885POLB 1769/4885ALDH1A1 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.